Saturday, November 16, 2024
spot_img

SII aims to have 100 million doses of AstraZeneca vax ready by Dec

Date:

Share post:

spot_img
spot_img

New Delhi, Nov 13: Serum Institute of India (SII) is ramping up production of AstraZeneca’s Covid-19 vaccine, aiming to have 100 million doses ready by December for a vaccination drive that could begin across India that same month, Bloomberg reported.
If final-stage trial data show that AstraZeneca’s vaccine candidate is giving effective protection from the virus, the Serum Institute of India — which is partnered to produce at least one billion doses — may get emergency authorisation from New Delhi by December, said Adar Poonawalla, Chief Executive Officer, SII, in an interview with Bloomberg.
That initial amount will go to India, Poonawalla said. Full approval early next year will allow distribution on a 50-50 basis between the south Asian nation and Covax, the World Health Organization-backed body that’s purchasing shots for poor nations.
SII, which has tied up with five developers, has so far made 40 million doses of AstraZeneca vaccine in the past two months and aims to start manufacturing Novavax’s contender soon.
“We were a bit concerned it was a big risk,” said 39-year-old Poonawalla. But both AstraZeneca and Novavax’s shots “are looking pretty good”, Bloomberg reported.
Poonawalla, is putting $250 million of his family’s fortune into a bid to ramp up manufacturing capacity to 1 billion doses through 2021.
“I decided to go all out,” said Poonawalla. Among the initial skeptics: his father, Cyrus Poonawalla, the company’s founder. “He said: ‘Look, it’s your money. If you want to blow it up, fine?” Adar said in an interview to Washington Post.
One prominent vaccine candidate requiring ultra-cold storage is “a joke” that will not work for the developing world. Anyone who declares how long a vaccine will confer immunity is talking “nonsense.” The world’s entire population will not be immunised until 2024, he said, contrary to rosier predictions.
Poonawalla is equally frank about the gamble his company is taking in the pandemic.
Gavi and the Gates Foundation “want to assure vaccine supply at an affordable price,” said Poonawalla. His aim, meanwhile, is to cover some of his costs. (IANS)

spot_img
spot_img

Related articles

NEHU VC goes on leave

Senior-most professor Nirmalendu Saha takes over as VC in-charge By Our Reporter SHILLONG, Nov 15: Senior-most professor Nirmalendu Saha on...

Students to continue hunger strike

By Our Reporter SHILLONG, Nov 15: The NEHUSU and KSU NEHU Unit have decided to continue with their indefinite...

NPP upbeat, others say close call in Gambegre

By Our Reporter SHILLONG, Nov 15: All political parties, except National People’s Party (NPP), felt the result of the...

CM inaugurates IGP traffic point

By Our Reporter SHILLONG, Nov 15: Chief Minister Conrad K Sangma on Friday inaugurated the redeveloped and beautified IGP...